Search
 
Rabies

Rabies is a viral encephalitis transmitted by the saliva of infected bats and certain other infected mammals. Symptoms include depression and fever, followed by agitation, excessive salivation, and hydrophobia. Diagnosis is by serologic tests or biopsy. Vaccination is indicated for people at high risk of exposure. Postexposure prophylaxis involves wound care and passive and active immunoprophylaxis. The disorder is almost universally fatal. Treatment is supportive.

Rabies causes > 50,000 human deaths worldwide annually, mostly in Latin America, Africa, and Asia, where canine rabies is endemic. In the US, vaccination of domestic animals has reduced rabies cases in people to < 6/yr, mostly transmitted by infected bats. Infected raccoons, skunks, and foxes can also transmit rabies.

Rabid animals transmit the infection through their saliva, usually by biting. Rarely, the virus can enter through a skin abrasion or across mucous membranes of the eyes, nose, or mouth. The virus travels from the site of entry via peripheral nerves to the spinal cord (or to the brain stem when the face is bitten), then to the brain. It spreads from the CNS via peripheral nerves to other parts of the body. Involvement of the salivary glands and oral mucosa is responsible for transmissibility.

Symptoms and Signs

Pain or paresthesias may develop at the site of the bite. Rapidity of progression depends on the viral inoculum and proximity of the wound to the brain. The incubation period averages 1 to 2 mo but may be > 1 yr. Initial symptoms are nonspecific: fever, headache, and malaise. Within days, encephalitis (furious rabies; in 80%) or paralysis (dumb rabies; in 20%) develops. Encephalitis causes restlessness, confusion, agitation, bizarre behavior, hallucinations, and insomnia. Salivation is excessive, and attempts to drink cause painful spasms of the laryngeal and pharyngeal muscles (hydrophobia). In the paralytic form, ascending paralysis and quadriplegia develop without delirium and hydrophobia.

Diagnosis

  • Skin biopsy
  • Sometimes PCR testing of fluid or tissue samples

Rabies is suspected in patients with encephalitis or ascending paralysis and a history of an animal bite or exposure to bats; bat bites may be superficial and overlooked.

Direct fluorescence antibody testing of a biopsy specimen of skin from the nape of the neck is the diagnostic test of choice. Diagnosis can also be made by PCR of CSF, saliva, or tissue. Specimens tested for rabies antibodies include serum and CSF. CT, MRI, and EEG are normal or show nonspecific changes.

Treatment

  • Supportive care

Treatment is only supportive and includes heavy sedation (eg, with ketamineSome Trade Names
KETALAR
Click for Drug Monograph
and midazolamSome Trade Names
No US trade name
Click for Drug Monograph
) and comfort measures. Death usually occurs 3 to 10 days after symptoms begin. Only a handful of patients have survived; all but one of them received immunoprophylaxis before onset of symptoms. There is evidence that giving rabies vaccine and immune globulin after clinical rabies develops may cause more rapid deterioration.

Experimental therapies with ribavirinSome Trade Names
VIRAZOLE
Click for Drug Monograph
, amantadineSome Trade Names
SYMMETREL
Click for Drug Monograph
, interferon-alfa, and other drugs are sometimes tried in desperation (see http://www.mcw.edu/FileLibrary/Groups/Pediatrics/InfectiousDiseases/Milwaukee_rabies_protocol_V3_1.pdf).

Prevention

Preexposure: Rabid animals can often be recognized by their strange behavior; they may be agitated and vicious, weak, or paralyzed and may show no fear of people. Nocturnal animals (eg, bats, skunks, raccoons) may be out during the day. Bats may make unusual noises and have difficulty flying. An animal suspected of having rabies should not be approached. Local health authorities should be contacted to remove the animal.

Human diploid cell rabies vaccine (HDCV) is safe and recommended for preexposure prophylaxis for people at risk, including veterinarians, animal handlers, spelunkers, workers who handle the virus, and travelers to endemic areas. A total of three 1-mL doses are given IM, one each on days 0, 7, and between day 21 and 28.

Postexposure: Exposure is considered to be a bite that breaks the skin or any contact between mucous membrane or broken skin and animal saliva. If exposure occurs, prompt, meticulously executed prophylaxis almost always prevents human rabies. The wound is cleansed immediately and thoroughly with soap and water or benzalkonium chloride. Deep puncture wounds are flushed with soapy water using moderate pressure. Wounds are usually left open.

Postexposure prophylaxis (PEP) with rabies vaccine and rabies immune globulin (RIG) is given depending on the biting animal and circumstances (see Table 1: Brain Infections: Rabies Postexposure ProphylaxisTables). PEP is begun, and the animal's brain is tested for virus. Local or state health departments or the Centers for Disease Control and Prevention usually conduct testing and can advise on other treatment issues.

Table 1

Rabies Postexposure Prophylaxis

Animal Type

Evaluation and Disposition of Animal

Postexposure Prophylaxis*

Skunks, raccoons, bats, foxes, and most other carnivores

Regarded as rabid unless proved negative by laboratory tests

Consider immediate vaccination and rabies immune globulin.

Dogs, cats, and ferrets

Healthy and available for 10 days of observation

Do not begin immunoprophylaxis unless animal develops symptoms of rabies.§

Unknown (escaped)

Consult public health officials.

Rabid or suspected rabid

Vaccinate immediately.

Consider rabies immune globulin.

Livestock, small rodents (eg, squirrels, hamsters, guinea pigs, gerbils, chipmunks, rats, mice), lagomorphs (rabbits, hares), large rodents (eg, woodchucks, beavers), and other mammals

Considered individually

Consult public health officials.

Immunoprophylaxis is almost never required for bites of squirrels, hamsters, guinea pigs, gerbils, chipmunks, rats, mice, other small rodents, or lagomorphs.

*Clean all bites immediately with soap and water.

Because detecting bat bites is difficult, vaccination is indicated if a bite is reasonably likely, as when a person awakens with a bat in the room or a young child is found with a bat.

The animal should be euthanized and tested as soon as possible. Holding for observation is not recommended. Vaccine is stopped if rabies immunofluorescence tests of the animal are negative.

§If the animal remains healthy during the 10-day observation period, it was not infective at the time of the bite. However, treatment with rabies immune globulin (RIG) and human diploid cell vaccine (HDCV) or rabies vaccine is begun at the first sign of rabies in a dog, cat, or ferret that has bitten someone. A symptomatic animal should be immediately euthanized and tested.

If expert consultation is not available locally and rabies is possible, immediate vaccination should be considered.

Adapted from Rabies prevention—United States 1999: Recommendations of the Immunization Practices Advisory Committee (ACIP). Morbidity and Mortality Weekly Report 48(RR-1):1–21, 1999.

For PEP, RIG 20 IU/kg is infiltrated around the wound for passive immunization; if injection volume is too much for distal areas (eg, fingers, nose), some RIG may be given IM. This treatment is accompanied by HDCV for active immunization. HDCV is given in a series of five 1-mL IM injections (deltoid area is preferred), beginning on the day of exposure (day 0), in a limb other than the one used for RIG. Subsequent injections occur on days 3, 7, 14, and 28. The WHO also recommends a 6th injection on day 90. Rarely, a serious systemic or neuroparalytic reaction occurs; then, completion of vaccination is weighed against the patient's risk of developing rabies. Rabies antibody titer is measured to help assess risk of stopping vaccination.

PEP for a person previously vaccinated against rabies includes 1-mL IM injections of HDCV on days 0 and 3 but no RIG.

Last full review/revision December 2009 by Michael Jacewicz, MD

Content last modified December 2009

Back to Top

Previous: Progressive Multifocal Leukoencephalopathy (PML)

Next: Subdural Empyema

Audio
Figures
Photographs
Tables
Videos

Copyright     © 2010-2011 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, N.J., U.S.A.    Privacy    Terms of Use